Vedanta Limited

Vedanta posted a 6% revenue increase to 39,218 crore INR in Q2 2025 and a 12% rise in EBITDA to 11,612 crore INR; EBITDA margin rose 70 basis points to 34%. Drivers were record aluminium/alumina production, operational efficiency and new capacity; the company announced an interim dividend of 16 INR per share. Management is targeting EBITDA of over $6bn for FY26, capex of $1.7–1.9bn and a net-debt-to-EBITDA ratio of around 1x; separation of five units is planned by end-FY26. » More on de.investing.com

Vedanta Biosciences’ experimental drug failed to meet the primary endoscopic endpoint in the phase 2 COLLECTiVE202 trial for mild to moderate ulcerative colitis; 114 patients were treated in the U.S., Europe and Australia. The therapy nevertheless showed a favorable safety profile with no treatment-related serious adverse events. Vedanta plans to concentrate resources on its program to prevent C. difficile recurrences (VE303); PureTech Health also announced personnel changes and the creation of the subsidiary Celea Therapeutics. » More on de.investing.com

Vedanta Ltd reported its highest-ever EBITDA of ₹100.07 billion in the first quarter of 2025, with revenue rising by 6% and adjusted net profit up by 13%. The company reduced its net debt and achieved record production volumes in aluminum and zinc. Despite global uncertainties, Vedanta remains on a growth trajectory and has reaffirmed its outlook for fiscal year 2026. » More on de.investing.com

Vedanta Limited reported record EBITDA for the first quarter of fiscal year 2026, driven by strong volume growth in its core segments and consistent cost optimization. The company improved its net debt ratio and achieved production records in aluminum, zinc, and ferrochrome. Additionally, ESG performance was further enhanced and a dividend of ₹7 per share was declared. » More on de.investing.com

Vedanta Limited is reportedly preparing to merge BALCO and Vedanta Aluminium into a new entity, Vedanta Aluminium Metal Limited (VAML), amid allegations of government complicity and lack of legal objections from key ministries. The process involves unresolved legal disputes and questions about transparency, with concerns raised over the withdrawal of court cases and bypassing of shareholder rights. Calls have been made for greater accountability and disclosure regarding the merger and planned public listing. » More on medium.com